GENE Therapy Payment Act

Summary

Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 12 February 2020

   Introduced

   Introduced in House

   Source: IntroReferral

2. 12 February 2020

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

3. 12 February 2020

   Introduced

   Introduced in House

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

• Introduced in House · 12 February 2020 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 12 February 2020

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 12 February 2020

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 12 February 2020

  Open at official source

Sponsors

• Kurt Schrader · D · Sponsor
• Roger Marshall · R · Sponsor
• Rep. Crow, Jason [D-CO-6] · D · Sponsor
• Markwayne Mullin · R · Sponsor
• Rep. Bera, Ami [D-CA-6] · D · Sponsor
• Rep. Kelly, Mike [R-PA-16] · R · Sponsor
• David Schweikert · R · Sponsor
• · hsif00 · Standing

Related records

• related to → Lower Costs, More Cures Act of 2019
• related to → Prescription Drug Pricing Reduction Act of 2019
• related to ← Prescription Drug Pricing Reduction Act of 2020